Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Rivaroxaban 20 mg Tablet Formulations Under Fed Conditions in Healthy Thai Volunteers
TCTR20211203004Phase 1Completed
- Sponsor
- Novugen Pharma Sdn. Bhd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (2 arms), sponsored by Novugen Pharma Sdn. Bhd. Started Mar 2022; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on TCTR20211203004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211203004.